The France-based biotechnology company MedDay SAS announced encouraging results for a multiple sclerosis drug trial, saying it decreased its progress and in some cases led to “significant improvement” for sufferers. Multiple sclerosis, the most widespread disabling neurological disease in young adults, is estimated to affect about 2.5 million people worldwide.
“This is the first time that a drug has been able to decrease the rate of disease progression in addition to improving a significant proportion of patients with progressive multiple sclerosis”, said Frédéric Sedel, CEO of MedDay.
The experimental drug MD1003 is a high-concentration form of vitamin H and underwent Phase III clinical trial. This is the last stage before filling for authorization to its commercialization aiming the treatment of primary and secondary progressive multiple sclerosis.
The results of the study were presented last Friday at the American Academy of Neurology’s annual meeting. According to Prof. Ayman Tourbay, principal investigator of this study, “The rapid rate of recruitment into this multi-centre study illustrates the serious need for a well-tolerated drug by patients with primary and secondary progressive multiple sclerosis”.
“The significant proportion of patients showing improvement at twelve months, coupled with the decrease in risk of disease progression demonstrated here, makes MD1003 a potentially important new therapy for patients and in the field of multiple sclerosis.”
The application process for drug licensing is expected to start by the end of 2015.